Cargando…

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

Palivizumab monthly injections throughout the RSV season prevent severe respiratory syncytial virus (RSV) disease in preterm infants ≤ 35 wGA. However, some RSV guidelines currently recommend stopping palivizumab after 3 months of age in the midst of the RSV season. This article evaluates the need f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makari, Doris, Checchia, Paul A, DeVincenzo, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130285/ https://www.ncbi.nlm.nih.gov/pubmed/24316863 http://dx.doi.org/10.4161/hv.27426

Ejemplares similares

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants
por: DeVincenzo, John P., et al.
Publicado: (2016)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis
por: Pickles, Raymond J, et al.
Publicado: (2015)

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
por: Makari, Doris, et al.
Publicado: (2015)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998–2008
por: Groothuis, Jessie R, et al.
Publicado: (2011)

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2011)

Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity
por: Harding, Jeffrey N., et al.
Publicado: (2020)

Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analyses
por: Beauchemin, Catherine A. A., et al.
Publicado: (2019)

Determining the seasonality of respiratory syncytial virus in Slovenia
por: Grilc, Eva, et al.
Publicado: (2020)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children
por: Kim, Young-In, et al.
Publicado: (2015)

Viral Specific Factors Contribute to Clinical Respiratory Syncytial Virus Disease Severity Differences in Infants
por: Thompson, Tonya M, et al.
Publicado: (2015)

Erratum to: Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2012)

Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
por: Simões, Eric A. F., et al.
Publicado: (2015)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33
por: Saravia, Jordy, et al.
Publicado: (2015)

Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus
por: Verwey, Charl, et al.
Publicado: (2023)

Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis
por: Maas, Brian M., et al.
Publicado: (2021)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
por: Artin, Ben, et al.
Publicado: (2021)

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review
por: Wegzyn, Colleen, et al.
Publicado: (2014)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Modeling the variations in pediatric respiratory syncytial virus seasonal epidemics
por: Leecaster, Molly, et al.
Publicado: (2011)

Modelling the Seasonal Epidemics of Respiratory Syncytial Virus in Young Children
por: Moore, Hannah C., et al.
Publicado: (2014)

Respiratory Syncytial Virus Seasonality — United States, 2014–2017
por: Rose, Erica Billig, et al.
Publicado: (2018)

Respiratory Syncytial Virus Seasonality, Beijing, China, 2007–2015
por: Yu, Jianxing, et al.
Publicado: (2019)

Respiratory syncytial virus seasonality in three epidemiological zones of Kenya
por: Rose, Erica Billig, et al.
Publicado: (2020)

Seasonal shift in epidemics of respiratory syncytial virus infection in Japan
por: Miyama, Takeshi, et al.
Publicado: (2021)

Epidemiology and Seasonality of Childhood Respiratory Syncytial Virus Infections in the Tropics
por: Suryadevara, Manika, et al.
Publicado: (2021)

Seasonality of Respiratory Syncytial Virus — United States, 2017–2023
por: Hamid, Sarah, et al.
Publicado: (2023)

Human respiratory syncytial virus and influenza seasonality patterns—Early findings from the WHO global respiratory syncytial virus surveillance
por: Chadha, Mandeep, et al.
Publicado: (2020)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

Respiratory Syncytial Virus Human Experimental Infection Model: Provenance, Production, and Sequence of Low-Passaged Memphis-37 Challenge Virus
por: Kim, Young-In, et al.
Publicado: (2014)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines
por: Choi, Yoonyoung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cuitks73f3th91j8h9v670fbb0